Breast cancer

BIS Research Study Highlights the Global Next-Generation Oncology Devices and Solutions Market to Reach $5.97 Billion by 2031

Retrieved on: 
Tuesday, June 28, 2022

FREMONT, Calif., June 28, 2022 /PRNewswire/ --The global next-generation oncology devices and solutions market is projected to reach $5.97 billion in terms of revenue by 2031, at a CAGR of 6.41%, suggests the premium market intelligence study by BIS Research.

Key Points: 
  • FREMONT, Calif., June 28, 2022 /PRNewswire/ --The global next-generation oncology devices and solutions market is projected to reach $5.97 billion in terms of revenue by 2031, at a CAGR of 6.41%, suggests the premium market intelligence study by BIS Research.
  • The global next-generation oncology devices and solutions market is expected to witness the rise of many specialized startups.
  • Market share analysis for key companies in the global next-generation oncology devices and solutions market.
  • Following are the opportunities for the global next-generation oncology devices and solutions market:
    This exclusive report on the global next-generation oncology devices and solutionsmarket will help you in the following ways:
    Aid in the development of advanced next-generation oncology devices and solutions.

Particle Therapy Market Revenue To Reach $1,634.4 Million by 2030, says P&S Intelligence

Retrieved on: 
Tuesday, June 28, 2022

NEW YORK, June 28, 2022 /PRNewswire/ --According to the market research report published by P&S Intelligence, in 2021, the size of the particle therapy market was $797.1 million, which will reach $1,634.4 million by the year 2030, at a growth rate of 8.3% over this decade.

Key Points: 
  • NEW YORK, June 28, 2022 /PRNewswire/ --According to the market research report published by P&S Intelligence, in 2021, the size of the particle therapy market was $797.1 million, which will reach $1,634.4 million by the year 2030, at a growth rate of 8.3% over this decade.
  • Furthermore, the active participation of companies to introduce particle therapy products too helps in the growth of the market.
  • The share of proton therapy in the particle therapy market was in excess of 90% in the year 2021, and it will have a higher growth rate of about 8.5% in the coming years.
  • In 2021, the European particle therapy market garnered the highest revenue.

Particle Therapy Market Revenue To Reach $1,634.4 Million by 2030, says P&S Intelligence

Retrieved on: 
Tuesday, June 28, 2022

NEW YORK, June 28, 2022 /PRNewswire/ --According to the market research report published by P&S Intelligence, in 2021, the size of the particle therapy market was $797.1 million, which will reach $1,634.4 million by the year 2030, at a growth rate of 8.3% over this decade.

Key Points: 
  • NEW YORK, June 28, 2022 /PRNewswire/ --According to the market research report published by P&S Intelligence, in 2021, the size of the particle therapy market was $797.1 million, which will reach $1,634.4 million by the year 2030, at a growth rate of 8.3% over this decade.
  • Furthermore, the active participation of companies to introduce particle therapy products too helps in the growth of the market.
  • The share of proton therapy in the particle therapy market was in excess of 90% in the year 2021, and it will have a higher growth rate of about 8.5% in the coming years.
  • In 2021, the European particle therapy market garnered the highest revenue.

Kim Adams returns to Local 4 News

Retrieved on: 
Tuesday, June 28, 2022

DETROIT, June 27, 2022 /PRNewswire/ -- Former Local 4 News Meteorologist Kim Adams will rejoin WDIV as a meteorologist on all of our station's main content platforms -- Local 4 News on television, the station website clickondetroit.com, and the station's streaming channel Local 4+, it was announced today by WDIV Vice President and General Manager Bob Ellis. Adams will start these new roles beginning August 8. 

Key Points: 
  • Adams previously served as Meteorologist on Local 4 most recently in 2009, when she left the station to become a full-time mother of her five children.
  • "We're thrilled to have Kim returning to the Local 4 team," said News Director Kim Voet.
  • Teamed with Paul Gross, Andrew Humphrey, Brandon Roux, and Brett Collar, Adams will help sharpen the station's focus on covering local weather under the station's new weather brand, 4 Warn Weather.
  • With Kim back home at WDIV we're putting more "Local" in Local 4 and we'll have additional announcements coming about plans for more special events and coverage of local weather.

Global Whole Slide Imaging Market (2022 to 2027) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, June 27, 2022

Whole slide imaging (WSI) is scanning glass slides used to produce high-resolution and precise digital images of tissue sections.

Key Points: 
  • Whole slide imaging (WSI) is scanning glass slides used to produce high-resolution and precise digital images of tissue sections.
  • How has the global whole slide imaging market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global whole slide imaging market?
  • What is the structure of the global whole slide imaging market and who are the key players?

Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors

Retrieved on: 
Monday, June 27, 2022

While the partial hold is in place, no new patients will be enrolled in the NUV-422 program, although current study participants may continue to be treated in the Phase 1 study.

Key Points: 
  • While the partial hold is in place, no new patients will be enrolled in the NUV-422 program, although current study participants may continue to be treated in the Phase 1 study.
  • Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates.
  • Nuvation Bio's proprietary portfolio includes mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer.
  • Nuvation Bio disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release.

Relay Therapeutics Discloses Anticipated Registrational Path for RLY-4008 in Cholangiocarcinoma and Growing Breast Cancer Franchise at Virtual Analyst and Investor Event

Retrieved on: 
Monday, June 27, 2022

CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will announce today the anticipated registrational path for RLY-4008 and three new programs within a growing HR+/HER2- breast cancer franchise at a virtual analyst and investor event from 8:00 a.m. to 9:00 a.m. ET.

Key Points: 
  • We are excited to be announcing the anticipated registrational path for RLY-4008 and the maturation of the data to support that pathway.
  • In addition, building on the foundation of our PI3K franchise, we will outline a broad commitment to developing comprehensive treatment options for breast cancer patients.
  • Relay Therapeutics conducted an end-of-phase 1 meeting with the FDA to discuss next steps for the clinical development of RLY-4008.
  • The virtual analyst and investor event will be webcast live and may be accessed through Relay Therapeutics website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations .

Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen

Retrieved on: 
Monday, June 27, 2022

Trastuzumab deruxtecan is a specifically engineered HER2 directed antibody drug conjugate (ADC) being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.

Key Points: 
  • Trastuzumab deruxtecan is a specifically engineered HER2 directed antibody drug conjugate (ADC) being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.
  • This positive CHMP opinion is an important step forward in bringing this potentially practice-changing medicine to patients in Europe to use earlier in the treatment of HER2 positive metastatic breast cancer and builds on the recent approval of trastuzumab deruxtecan in the U.S.
  • Nearly all patients treated with trastuzumab deruxtecan were alive at one year (94.1%; 95% CI: 90.3-96.4) compared to 85.9% of patients treated with T-DM1 (95% CI: 80.9-89.7).
  • Patients with hormone receptor (HR) positive breast cancer must additionally have received or be ineligible for endocrine therapy.

 Tigerlily Foundation and Labcorp Collaborate to Increase Clinical Trial Diversity for Women of Color

Retrieved on: 
Friday, June 24, 2022

Labcorp , a leading global life sciences company, and Tigerlily Foundation (Tigerlily), a leading breast cancer patient advocacy organization, today announced a new collaboration to increase clinical trial diversity for women of color and co-create health equity solutions.

Key Points: 
  • Labcorp , a leading global life sciences company, and Tigerlily Foundation (Tigerlily), a leading breast cancer patient advocacy organization, today announced a new collaboration to increase clinical trial diversity for women of color and co-create health equity solutions.
  • To continue to accelerate and make an impact as it relates to disparities and women of color, the #InclusionPledge is imperative.
  • As an organization, Tigerlily Foundation was founded to address inequityof age, of stage and of color.
  • Labcorp is committed to inclusive clinical research and is driving innovative solutions to increase representation of racial and ethnic minorities in clinical trials.

BioFluidica Next-Generation Liquid Biopsy Platform Uncovers Undiagnosed HER2+ Patients

Retrieved on: 
Friday, June 24, 2022

SAN DIEGO, June 24, 2022 /PRNewswire/ -- Biofluidica today announced the results of a breast cancer study comparing invasive needle biopsies with their non-invasive, highly sensitive Next-Generation Liquid Biopsy platform, LiquidScan to detect HER2 positive (HER2+) patients.

Key Points: 
  • SAN DIEGO, June 24, 2022 /PRNewswire/ -- Biofluidica today announced the results of a breast cancer study comparing invasive needle biopsies with their non-invasive, highly sensitive Next-Generation Liquid Biopsy platform, LiquidScan to detect HER2 positive (HER2+) patients.
  • The BioFluidica LiquidScan technology provides a next-generation liquid biopsy in which sensitive and accurate analyses can be performed on cells.
  • I am especially excited that we might be able to find more patients that could be eligible for improved therapy using the high sensitivity LiquidScan Next-Generation Liquid Biopsy platform".
  • BioFluidica Inc. is a privately held biotechnology company that has developed a revolutionary liquid biopsy platform.